# N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography

> **NCT00830193** · PHASE2,PHASE3 · COMPLETED · sponsor: **Unity Health Toronto** · enrollment: 45 (actual)

## Conditions studied

- Contrast Induced Nephropathy
- Critically Ill

## Interventions

- **DRUG:** N-acetylcysteine
- **DRUG:** D5W Placebo

## Key facts

- **NCT ID:** NCT00830193
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2009-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00830193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00830193, "N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00830193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*